CBD Pretreatment Reduced THC-Induced Paranoia and Memory Impairment in Healthy Volunteers | Research

The takeaway

Pre-treatment with 600 mg oral CBD significantly reduced THC-induced paranoia and prevented the memory impairment normally caused by intravenous THC in healthy volunteers.

Read this if you use cannabis and want to understand how CBD might protect against THC side effects.

CBD reduced clinically significant psychotic symptoms from THC by 78% (OR=0.22)

What the researchers found

In a between-subjects, double-blind design, 48 healthy participants received either 600 mg oral CBD (n=22) or placebo (n=26) before intravenous THC (1.5 mg). CBD pretreatment produced two key protective effects.

First, clinically significant psychotic symptoms (3+ point increase on PANSS positive scale) were significantly less likely in the CBD group (OR=0.22), and paranoia scores were significantly lower. Second, verbal learning memory (HVLT-R) declined by 10.6% in the placebo group but only 0.4% in the CBD group, essentially eliminating THC's memory-impairing effect.

Why it matters

This study provides experimental evidence for the epidemiological observation that high-THC/low-CBD cannabis products are more harmful than balanced-ratio products. It also suggests CBD could serve as a protective agent against THC's negative psychiatric effects, with implications for medical cannabis formulation.

The numbers in context

48 participants. CBD 600 mg oral, 210 min before THC 1.5 mg IV. Clinically significant psychosis: OR=0.22 in CBD group (p<0.05). Paranoia: significantly lower in CBD group (p<0.05). Memory decline: -10.6% (placebo) vs. -0.4% (CBD) (p<0.05).

How the study worked

Between-subjects, double-blind, placebo-controlled RCT. 48 healthy participants (22 CBD, 26 placebo). CBD 600 mg oral administered 210 minutes before IV THC 1.5 mg. Outcomes: PANSS positive scores, State Social Paranoia Scale, Hopkins Verbal Learning Task-Revised.

What this study cannot tell us

The between-subjects design means individual differences may have contributed. A single high IV THC dose is not equivalent to chronic cannabis smoking. The oral CBD was given 3.5 hours before IV THC, which may not reflect typical cannabis use where both cannabinoids are consumed simultaneously. The sample was healthy volunteers without psychosis risk factors.

How to read the evidence

Double-blind, placebo-controlled RCT with clear outcomes; strong evidence for CBD protection against acute THC effects.

When this study was published

Published in 2013. This study influenced the growing interest in CBD-to-THC ratios in cannabis products and regulation.

The bigger picture

This is one of the most important experimental studies demonstrating that CBD can protect against specific harms of THC. It provides a pharmacological basis for cannabis regulation: products with higher CBD-to-THC ratios may be inherently safer for mental health.

Questions still open

Would CBD protect against THC effects in people with psychosis vulnerability? What CBD-to-THC ratio provides optimal protection? Should cannabis regulations mandate minimum CBD content? Does smoked or vaped CBD provide the same protection?

Common questions

Does CBD protect against THC-induced paranoia?

In this controlled experiment, yes. Participants who received 600 mg CBD before THC were 78% less likely to experience clinically significant psychotic symptoms and had significantly less paranoia than those who received placebo before THC.

Does CBD prevent cannabis memory problems?

In this study, CBD pretreatment essentially eliminated THC's negative effect on verbal learning. The placebo group showed a 10.6% decline in memory performance after THC, while the CBD group showed only a 0.4% decline. This suggests CBD preserves hippocampal-dependent memory function that THC normally impairs.

Read the original research

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.

Journal of psychopharmacology (Oxford, England), 27(1), 19-27

View on PubMed ↗Publisher’s paper ↗

Citation

Englund, Amir; Morrison, Paul D; Nottage, Judith; Hague, Dominic; Kane, Fergus; Bonaccorso, Stefania; Stone, James M; Reichenberg, Avi; Brenneisen, Rudolf; Holt, David; Feilding, Amanda; Walker, Lucy; Murray, Robin M; Kapur, Shitij. (2013). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.. Journal of psychopharmacology (Oxford, England), 27(1), 19-27. https://doi.org/10.1177/0269881112460109